









Markets
/
Stocks
/
nasdaq-adma
/

ADMA Biologics Inc

ADMA

15.910USD

-0.250-1.55%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

3.80BMarket Cap

18.17P/E TTM



ADMA Biologics Inc

15.910

-0.250-1.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

24 / 175

Overall Ranking

104 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

29.060

Target Price

+79.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 176.77% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 197.67M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is 17.91, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 225.21M shares, decreasing 2.66% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 21.31M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.83, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 121.98M, representing a year-over-year increase of 13.80%, while its net profit experienced a year-over-year increase of 6.73%.

Score

Industry at a Glance

Previous score

8.83

Change



Financials

8.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.74, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 18.19, which is 11.18% below the recent high of 20.23 and 206.53% above the recent low of -19.38.

Score

Industry at a Glance

Previous score

2.74

Change

0.04

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for ADMA Biologics Inc is 31.00, with a high of 35.00 and a low of 19.24.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

29.060

Target Price

+79.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

ADMA Biologics Inc

ADMA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.29, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 17.62 and the support level at 14.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.29

Change

-0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.062

Sell

RSI(14)

41.648

Neutral

STOCH(KDJ)(9,3,3)

45.174

Buy

ATR(14)

0.612

High Vlolatility

CCI(14)

-21.106

Neutral

Williams %R

65.929

Sell

TRIX(12,20)

-0.428

Sell

StochRSI(14)

81.600

Overbought

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

15.724

Buy

MA10

15.941

Sell

MA20

16.554

Sell

MA50

17.246

Sell

MA100

18.655

Sell

MA200

18.403

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 94.37%, representing a quarter-over-quarter increase of 3.10%. The largest institutional shareholder is The Vanguard, holding a total of 21.31M shares, representing 8.93% of shares outstanding, with 16.45% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

34.20M

-2.37%

The Vanguard Group, Inc.

Star Investors

16.79M

-7.48%

State Street Global Advisors (US)

11.44M

-23.07%

Invesco Advisers, Inc.

9.69M

+5.25%

Geode Capital Management, L.L.C.

5.67M

+4.33%

Dimensional Fund Advisors, L.P.

4.86M

+4.11%

American Century Investment Management, Inc.

4.25M

+12.69%

Nuveen LLC

3.46M

+7.27%

Grossman (Adam S)

3.77M

-0.16%

Allspring Global Investments, LLC

3.05M

+7.29%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.64, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.